asthma COPD
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Asthma: non-smoking, allergic, intermittent to mild persistent asthma (history of episodic wheeze and shortness of breath). FEV1 predicted > 70% and PC20 histamine between 0.25 to 8 mg/ml. COPD: middle-age onset of symptoms, cigarette consumption of at least 15 pack-years and a post-bronchodilator FEV1/VC ratio smaller than 0.7. Reversibility in FEV1 assessed after the apropriate abstaining of bronchodilators, and measured follwing high dose of beta2-agonist inhalation was below 11% of predicted. Healthy individuals: no lung pathology
Exclusion criteria
Exclusion criteria: Exacerbation requiring oral steroids or antibiotics for 3 months before the study and no lower respiratory tract infection for 4 weeks before the study. Inhaled corticosteroids, antibiotics, theophylline, sodium cromoglycate, or antileukotrienes were not allowed 4 weeks before and during the study. Specific exclusion criteria: for COPD patients: allergy; for asthma patients: smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| With this project we will analyze around five proteins in a semi-quantitative manner and determine the microRNA profiles in airway epithelial cells from patients with asthma or COPD or that of healthy individuals. In both analyses we will use endogenous standards allowing us to compare the analyses between the study groups. These analyses will be linked to clinical details. | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary study parameters | — |
Countries
Netherlands
Outcome results
None listed